Zhang et al. report a randomized phase 2 trial for diffuse large B cell lymphoma (DLBCL) that compared standard of care (R-CHOP) to R-CHOP combined with one of 5 agents matched to an individual lymphoma’s genetics. Overall, the matching strategy significantly outperformed R-CHOP, laying the foundation for a paradigm-shifting phase 3 trial.

Increasing evidence suggests that tumors harbor diverse microbiomes, adding complexity to the tumor microenvironment. In this issue of Cancer Cell, Liu et al. highlight the role of the intratumor mycobiome, specifically Aspergillus sydowii, in promoting lung adenocarcinoma progression. A. sydowii enhances the recruitment and activation of myeloid-derived suppressor cells via IL-1β signaling driven

In this issue, Jason Shapiro, Hsiang-Chun (Jimmy) Chang and colleagues identify a conserved role for the iron-binding histone demethylase KDM3B in sensing iron levels and regulating mTORC1 through transcriptional repression of key components of the mTORC1 pathway. In this Q&A, we discuss this manuscript’s findings and publishing journey with first authors Jason Shapiro and Jimmy Chang and corresponding

Congratulations to John Jumper and Demis Hassabis for winning the 2023 Albert Lasker Basic Medical Research Award.

Dr. Dustin King spoke with Molecular Cell about his research interests in understanding how bacteria use protein carboxylation to sense greenhouse gases like carbon dioxide, his philosophy towards sustainability, and his hopes for a more sustainable future.

In this issue of Developmental Cell, Schülle et al. address the mechanism that lays down the mammalian body plan and show that the first step in this process is associated with the activity of two T-box transcription factors whose interactions outline territories that will be further elaborated during gastrulation.

Prof. Niels Mailand and Ann Schirin Mirsanaye share with Molecular Cell some of their thoughts on making molecular biology more sustainable, outline their first-hand experiences of having their lab LEAF (Laboratory Efficiency Assessment Framework) certified, and impart some advice to our readers who are considering doing the same.

In this Tools of the Trade article, Sarah Paramore (from the Devenport and Nelson labs) discusses the use of mouse strains carrying genomic alterations in PCP genes and how they can increase our understanding of mammalian planar cell polarity.

Molecular Cell has a conversation with Martin Farley about LEAF, the program he developed to run molecular biology laboratories in a sustainable way; the obstacles to making molecular biology sustainable; programs available to scientists; and caution to be exercised when taking steps towards sustainability.

Abstract not available

Here, Molecular Cell has a discussion with Dr. Andrea Bodnar about GMGI and its various efforts to minimize harm through research and implementing sustainable practices and efforts made at the institutional level to train budding scientists with diverse scientific skills and eco-conscious mindsets.

We talk to corresponding author Amy Lee and co-authors Shaoni Mukhopadhyay and Maria Amodeo about their scientific journey, research interests, and some behind-the-scenes details of their paper “eIF3d controls the persistent integrated stress response” (this issue of Molecular Cell).

Akey et al.1 use complementary experimental approaches and AI-based structure prediction to reveal new details of the structure of the yeast nuclear pore complex, providing key insights into evolution, assembly, and nucleocytoplasmic transport mechanisms.

A recent study by Liang et al.1 reveals that interacting enhancer RNAs (eRNAs) and promoter-transcribed upstream antisense RNAs (uaRNAs) can identify enhancer-promoter interactions. Complementary sequences within the interacting eRNAs and uaRNAs, predominantly Alu sequences, confer the specificity for eRNA-uaRNA pairing and hence enhancer-promoter recognition.

Abstract not available

Histone variants provide versatility in the basic unit of chromatin, helping to define dynamic landscapes and cell fates. Maintaining genome integrity is paramount for the cell, and it is intimately linked with chromatin dynamics, assembly, and disassembly during DNA transactions such as replication, repair, recombination, and transcription. In this review, we focus on the family of H3 variants and

Mammals favor healing with scaring over functional tissue regeneration.1 In this issue of Cell Stem Cell, Mack et al. use “super-healer” mice to identify cis-regulatory variations that direct regenerative versus fibrotic gene expression in wound fibroblasts and they uncover complement factor H as a molecular driver of skin regeneration.2

Mitotic DNA synthesis (MiDAS) is an unusual form of DNA replication that occurs during mitosis. Initially, MiDAS was characterized as a process associated with intrinsically unstable loci known as common fragile sites that occurs after cells experience DNA replication stress (RS). However, it is now believed to be a more widespread “salvage” mechanism that is called upon to complete the duplication

Mitochondria are central hubs of cellular metabolism that also play key roles in signaling and disease. It is therefore fundamentally important that mitochondrial quality and activity are tightly regulated. Mitochondrial degradation pathways contribute to quality control of mitochondrial networks and can also regulate the metabolic profile of mitochondria to ensure cellular homeostasis. Here, we cover

Liang et al. show that mitochondria can be expelled from cells via extracellular vesicles as a route of quality control that is an alternative to lysosomal degradation.

In an article in this issue of Developmental Cell and in a second paper in Cancer Cell, Mahadevan et al. demonstrate that KrasG12D suppression remodels the immunosuppressive microenvironment of KrasG12D pancreatic cancers, recruits activated CD8+ cytotoxic T cells, and epigenetically upregulates Fas expression in cancer cells, leading to tumor clearance via Fas/FasL-mediated apoptosis.

Successful implementation of adoptive cell therapy (ACT) of cancer requires comprehensively addressing biological and practical challenges. This approach has been largely overlooked, resulting in a gap between the potential of ACT and its actual effectiveness. We summarize the most promising technical strategies in creating an “ideal” ACT product, focusing on chimeric antigen receptor (CAR)-engineered